Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Currently approved targeted treatment for ROS1-rearranged non-small-cell lung cancer (NSCLC) has either inadequate intracranial activity or CNS-related toxicities. We evaluated the efficacy and safety of foritinib, a novel ALK and ROS1 inhibitor, in patients with advanced ROS1-rearranged NSCLC.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Respir Med

Title: The Lancet. Respiratory medicine

Publisher: Elsevier BV

ISSN (Electronic): 2213-2619

ISSN (Print): 2213-2600

Publication date (Electronic): Sep 2024

Volume: 12

Issue: 9

Affiliations

[1 ] Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

[2 ] Department of Respiratory Medicine, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

[3 ] Department of Hematology, The First Affiliated Hospital, Jinan University, Guangzhou, China.

[4 ] Department of Medical Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

[5 ] Department of Oncology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.

[6 ] Department of Oncology, Jilin Cancer Hospital, Changchun, China.

[7 ] Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.

[8 ] Department of Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, China.

[9 ] Department of Thoracic Oncology, Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

[10 ] Department of Respiratory Medicine, Cancer Hospital Affiliated to Harbin Medical University, Harbin, China.

[11 ] Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.

[12 ] Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

[13 ] Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, China.

[14 ] Department of Medical Oncology, Linyi Cancer Hospital, Linyi, China.

[15 ] Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

[16 ] Department of Respiratory Medicine, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

[17 ] Department of Medical Oncology, First Affiliated Hospital of China Medical University, Shenyang, China.

[18 ] Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.

[19 ] Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

[20 ] Department of Respiration, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.

[21 ] Department of Oncology, First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.

[22 ] Department of Oncology of the Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.

[23 ] Department of Thoracic Oncology, Shulan (Hangzhou) Hospital, Hangzhou, China.

[24 ] Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.

[25 ] Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

[26 ] Department of Medical Oncology, First Hospital of Jilin University, Changchun, China.

[27 ] Department of Oncology, Yongzhou Central Hospital, Yongzhou, Hunan, China.

[28 ] Department of Oncology, Yanbian University Hospital, Yanji, China.

[29 ] Department of Oncology, Jinan Central Hospital, Jinan, China.

[30 ] Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

[31 ] Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. Electronic address: wuyilong@gdph.org.cn.

Article

Publisher Item ID: S2213-2600(24)00171-1

DOI: 10.1016/S2213-2600(24)00171-1

PubMed ID: 39059398

SO-VID: 427b0966-dc75-4015-b9d8-5ea5f8a199ca

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 2

See all cited by